Replies to post #146521 on Biotech Values

[mcbio]

Daclatasvir had been tested in many more patients and in different combinations including nuc before. Safety issue hadn't come up. In addition, BMY singled out INX189 trials rather than daclatasvir trials to stop, thus at minimum they didn't think daclatasvir likely to be responsible.

Fair enough. And while I realize I may be reaching here, how do we know it's not an issue specific to these two drugs taken in combo (e.g., a class effect of combining a nuke + NS5A) where perhaps the nuke may work fine in combo with other HCV drug classes, such as PIs?